US Government as Represented by the Secretary of the Army

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

The Government of the United States, as Represen

Sheetij Dutta

David E Lanar

Lisa A Ware

Lalitha P V Nair

Adrian Batchelor

Carl R Alving

Gary R Matyas

Zoltan Beck

Farhat Khan

Mark Langowski

Michael Foley

The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23&#xb0; C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a solublerecombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or arCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.

recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery

The disclosure generally provides recombinant proteins comprising Tobamovirus capsid proteins and an immunogenic epitope of an antigen of interest. The recombinant protein can be used to assemble an array comprising a plurality of associated recombinant proteins that can enhance the immunogenicity of the epitope and induce and/or enhance an immune response to the antigen. The disclosure also provides compositions, such as vaccines, that include the recombinant protein as well as methods for inducing and/or enhancing an immune response in a mammal.

Tobamovirus-based virus-like particles and vaccines

Disclosed are AMA-1 immunogenic peptides and epitopes, nucleotide sequences encoding the peptides and epitopes, compositions, and vaccines including the peptides and/or epitopes. Antibodies that specifically bind to AMA-1 and the AMA-1 epitopes and immunogenic peptides disclosed herein are also provided. The disclosure provides for expression vectors, host cells, and methods for making the polypeptides and antibodies. Also provided are methods of treatment, prevention, vaccination, and/or immunization of a subject against malaria and the clinical indications associated with malaria.

AMA-1 epitopes, antibodies, compositions, and methods of making and using the same

The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinantcircumsporozoite proteins in bacterial cells such as. Processes are provided for producing a soluble recombinantCSP from. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinantcircumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.

Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof

Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression

In this application is the expression and purification of a recombinant(SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.

[object Object]

In this application is described the expression and purification of a recombinant(3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.

In this application is described the expression and purification of a recombinant(3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.

Growing community of inventors

Silver Spring, MD, United States of America

Sheetij Dutta